Oncology & Cancer

FDA: Cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Oncology & Cancer

Blincyto approved for rare leukemia

(HealthDay)—Blincyto (blinatumomab) has been approved by the U.S. Food and Drug Administration to treat Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, a rare cancer of the bone marrow.

Diabetes

Tight blood sugar control doesn't prevent strokes in diabetics

(HealthDay)—A six-year study of people with type 2 diabetes found that intensively lowering blood pressure had a long-lasting effect in preventing heart attacks, strokes and deaths. But intensive blood sugar control didn't ...

Medical research

New route to identify drugs that can fight bacterial infections

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, ...

Attention deficit disorders

ADHD drugs may up risk of heart problems in kids, study finds

(HealthDay)—Whether drugs used to treat attention deficit hyperactivity disorder boost the risk of heart conditions in children remains a subject of concern. Now, research from Denmark suggests medications such as Ritalin ...

Medications

Novartis Japan unit charged over research manipulation

Japanese prosecutors Tuesday laid charges against the local unit of Swiss pharmaceutical giant Novartis in a widening scandal over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure ...

page 36 from 40